Vale SA ADR (VALE)vsVertex Pharmaceuticals Inc (VRTX)
VALE
Vale SA ADR
$15.14
+1.82%
BASIC MATERIALS · Cap: $64.24B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vale SA ADR generates 1680% more annual revenue ($213.59B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 6.5%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).
VALE
Buy55
out of 100
Grade: C
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.9%
Fair Value
$11.75
Current Price
$15.14
$3.39 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 27.6%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
0.5% revenue growth
ROE of 5.9% — below average capital efficiency
6.5% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : VALE
The strongest argument for VALE centers on Market Cap, Price/Book, Operating Margin.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : VALE
The primary concerns for VALE are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
VALE profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VALE carries more volatility with a beta of 0.94 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VALE generates stronger free cash flow (723M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 55/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other OTHER INDUSTRIAL METALS & MINING Stocks
Want to dig deeper into these stocks?